Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biogen Idec in $427M Deal with Neurimmune

By Pharmaceutical Processing | December 21, 2010

NEW YORK (AP) — Biogen Idec Inc. is expanding a
partnership with Neurimmune Holding AG, and will research treatments for
illnesses like Parkinson’s disease under a deal that could be worth more than
$427.5 million.

Biogen Idec said the companies will research potential treatments for
neurodegenerative diseases including Parkinson’s, Alzheimer’s disease, and
amyotrophic lateral sclerosis, a neuromuscular disease also known as Lou
Gehrig’s Disease. The Weston, Mass., company will pay Neurimmune $32.5 million
upfront, and the deal includes as much as $395 million in additional payments.
The drug candidates included in the deal are in preclinical testing and have not
been studied in humans.

Biogen will be responsible for testing the drugs, and will handle sales if
the products are approved. Neurimmune, which is based in Switzerland, will be
responsible for other scientific activities and discovery of potential backup
products. The companies have worked together since 2007.

Biogen’s products include the multiple sclerosis drugs Tysabri and Avonex,
and the cancer drug Rituxan. The company sells Tysabri through a partnership
with Elan Corp. PLC, and it markets Rituxan with Roche AG.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE